Arbutus Biopharma

Canadian Bio Tech Company

ABUS Nasdaq ISIN CA03879J1003 SEC CIK 1447028
Follow Arbutus Biopharma Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $299K −43.5% vs same quarter last year
Net income $59.1M +863.6% vs same quarter last year
EPS, diluted $0.30 +850% vs same quarter last year
Operating cash flow $239.8M +4222.6% vs same quarter last year
Revenue by quarter
$1.6M
$1.8M
$10.7M
$529K
$1.1M
$179.1M
$1M
$299K
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$400M−$200M$0$200MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$14.1M−$33.5M
FY24$6.2M−$69.9M
FY23$18.1M−$72.8M
FY22$39M−$69.5M
FY21$11M−$76.2M
FY20$6.9M−$63.7M
FY19$6M−$153.7M
FY18$5.9M−$57.1M
FY17$10.7M−$84.4M
FY16$1.5M−$384.2M
FY15$23.3M−$62.7M
FY14$15M−$38.8M
FY13$15.5M−$14.1M
FY12$14.1M$29.6M
FY11$16.8M−$10.1M
MarginsShare of revenue
  • Operating margin
  • Net margin
−40000%−30000%−20000%−10000%0%10000%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearOperating marginNet margin
FY25−271%−237.9%
FY24−1236.7%−1133%
FY23−430.5%−401.6%
FY22−167.8%−178%
FY21−669.1%−693.9%
FY20−836.1%−922%
FY19−2394%−2557.4%
FY18−1510.2%−959.8%
FY17−1036.7%−788.9%
FY16−32973.8%−25765.5%
FY15−446.5%−269.5%
FY14−223.6%−259.7%
FY13−78.6%−90.9%
FY12−91.8%209.9%
FY11−63.6%−60%
Free cash flowOperating cash flow minus capital expenditure
−$100M−$50M$0$50MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$39.6M
FY24−$65M
FY23−$86.9M
FY22−$35.9M
FY21−$68.3M
FY20−$51.7M
FY19−$71.6M
FY18−$69M
FY17−$55.9M
FY16−$61.9M
FY15−$58.7M
FY14−$13.5M
FY13−$7.5M
FY12$32.9M
FY11−$7.9M
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Arbutus Biopharma
  • Healthcare median
−30000%−20000%−10000%0%10000%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearArbutus BiopharmaHealthcare median
FY25−237.9%−30.6%
FY24−1133%−47%
FY23−401.6%−58%
FY22−178%−80.4%
FY21−693.9%−71.9%
FY20−922%−62.2%
FY19−2557.4%−46.3%
FY18−959.8%−49.6%
FY17−788.9%−45.9%
FY16−25765.5%−36%
FY15−269.5%−38.4%
FY14−259.7%−35.5%
FY13−90.9%−37.1%
FY12209.9%−29.1%
FY11−60%−27.9%